Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 0.64 |
| ▸ | FLT3 | P36888 | 20/20 | 0.64 |
| ▸ | CDK2 | P24941 | 16/20 | 0.64 |
| ▸ | CCNA2 | P20248 | 15/20 | 0.64 |
| ▸ | CCNA1 | P78396 | 15/20 | 0.64 |
| ▸ | TYK2 | P29597 | 9/20 | 0.64 |
| ▸ | JAK1 | P23458 | 5/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | CCNK | O75909 | 1/20 | 0.54 |
| ▸ | STK10 | O94804 | 1/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | PRKCB | P05771 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.54 |
| ▸ | FER | P16591 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108223 | 0.86 | JAK2 (0.78) | JAK2FLT3CDK2CCNA2CCNA1 | |
| SCHEMBL1108219 | 0.85 | JAK2 (0.71) | JAK2FLT3CDK2CCNA2CCNA1 | |
| SCHEMBL1108225 | 0.85 | JAK2 (0.71) | JAK2FLT3CDK2CCNA2CCNA1 | |
| SCHEMBL18793222 | 0.80 | JAK2 (0.62) | JAK2FLT3CDK2CCNA2CCNA1 | |
| SCHEMBL1108230 | 0.79 | JAK2 (1.00) | JAK2FLT3CDK2CCNA2CCNA1 | |
| SCHEMBL11955406 | 0.79 | JAK2 (1.00) | JAK2FLT3CDK2CCNA2CCNA1 | |
| SCHEMBL1108228 | 0.79 | JAK2 (1.00) | JAK2FLT3CDK2CCNA2CCNA1 | |
| SCHEMBL18793221 | 0.79 | JAK2 (0.63) | JAK2FLT3CDK2CCNA2CCNA1 | |
| SCHEMBL20322485 | 0.77 | FLT3 (0.82) | JAK2FLT3CDK2CCNA2CCNA1 | |
| SCHEMBL29617551 | 0.77 | FLT3 (0.82) | JAK2FLT3CDK2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210069199-A1 | METHODS OF TREATING TRANSPLANT REJECTION | SOBI, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20160346270-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | AUSPEX PHARMACEUTICALS, INC. | 2016-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069199-A1 | METHODS OF TREATING TRANSPLANT REJECTION | JAK1, JAK2, JAK3 | JAK2 2/4885FLT3 50/4885CDK2 340/4885 |
| US-20160346270-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | SLC18A2, SLC6A2, SLC18A1 | JAK2 1928/4885FLT3 3467/4885CDK2 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.